Fax: (919) 668-7093
Statin medication use and the risk of biochemical recurrence after radical prostatectomy†
Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database
Article first published online: 28 JUN 2010
Copyright © 2010 American Cancer Society
Volume 116, Issue 14, pages 3389–3398, 15 July 2010
How to Cite
Hamilton, R. J., Banez, L. L., Aronson, W. J., Terris, M. K., Platz, E. A., Kane, C. J., Presti, J. C., Amling, C. L. and Freedland, S. J. (2010), Statin medication use and the risk of biochemical recurrence after radical prostatectomy. Cancer, 116: 3389–3398. doi: 10.1002/cncr.25308
Views and opinions of, and endorsements by the authors do not reflect those of the US Army or the Department of Defense.
- Issue published online: 2 JUL 2010
- Article first published online: 28 JUN 2010
- Manuscript Accepted: 1 FEB 2010
- Manuscript Revised: 22 DEC 2009
- Manuscript Received: 19 SEP 2009
- prostate neoplasms;
- radical prostatectomy;
- hydroxymethylglutaryl-coenzyme A reductase inhibitors;
Although controversial, evidence suggests statins may reduce the risk of advanced prostate cancer (PC), and recently statin use was associated with prostate-specific antigen (PSA) reductions among men without PC. The authors sought to examine the association between statin use and PSA recurrence after radical prostatectomy (RP).
The authors examined 1319 men treated with RP from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Time to PSA recurrence was compared between users and nonusers of statin at surgery using Cox proportional hazards models adjusted for multiple clinical and pathological features.
In total, 236 (18%) men were taking statins at RP. Median follow-up was 24 months for statin users and 38 for nonusers. Statin users were older (P < .001) and underwent RP more recently (P < .001). Statin users were diagnosed at lower clinical stages (P = .009) and with lower PSA levels (P = .04). However, statin users tended to have higher biopsy Gleason scores (P = .002). After adjusting for multiple clinical and pathological factors, statin use was associated with a 30% lower risk of PSA recurrence (hazard ratio “HR”, 0.70; 95% confidence interval “CI”, 0.50-0.97; P = .03), which was dose dependent (relative to no statin use; dose equivalent<simvastatin 20 mg: HR, 1.08; 95% CI, 0.66-1.73; P = .78; dose equivalent = simvastatin 20 mg: HR, 0.57; 95% CI, 0.32-1.00; P = .05; dose equivalent>simvastatin 20 mg: HR, 0.50; 95% CI, 0.27-0.93; P = .03).
In this cohort of men undergoing RP, statin use was associated with a dose-dependent reduction in the risk of biochemical recurrence. If confirmed in other studies, these findings suggest statins may slow PC progression after RP. Cancer 2010. © 2010 American Cancer Society.